Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16820172 | 1.00 | BRD4 (0.38) | BRD4POLBOPRM1KDM4ESLC22A1 | |
| SCHEMBL16840124 | 1.00 | BRD4 (0.38) | BRD4POLBOPRM1KDM4ESLC22A1 | |
| SCHEMBL16820226 | 0.79 | SYK (0.41) | POLBMAPTKMT2A | |
| SCHEMBL16820224 | 0.79 | SYK (0.41) | POLBMAPTKMT2A | |
| SCHEMBL16820225 | 0.79 | SYK (0.41) | POLBMAPTKMT2A | |
| SCHEMBL15486843 | 0.77 | — | — | |
| SCHEMBL16820250 | 0.75 | KDM4E (0.32) | KDM4E | |
| SCHEMBL16840097 | 0.72 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL2289941 | 0.72 | — | — | |
| SCHEMBL9325639 | 0.71 | OPRM1 (0.46) | BRD4POLBOPRM1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487504-B2 | Imidazolyl analogs as syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | SYK, BTK, LCK | BRD4 1376/4885POLB 2542/4885OPRM1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.